New topics in vasopressin receptors and approach to novel drugs: Research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia

Journal of Pharmacological Sciences

Volumn 109, Issue 1, 2009, Pages 53-59

  Arai, Yukinori ^a   Fujimori, Akira ^a   Sasamata, Masao ^a   Miyata, Keiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Arginine vasopressin; Arginine vasopressin (AVP) receptor antagonist; Conivaptan hydrochloride; Hyponatremia; YM087

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; ARGIPRESSIN[1 (3,3 CYCLOPENTAMETHYLENE 3 MERCAPTOPROPIONIC ACID) 2 (O METHYLTYROSINE)]; CONIVAPTAN; ELECTROLYTE; FUROSEMIDE; MOZAVAPTAN; SODIUM; VASOPRESSIN RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

CONTINUOUS INFUSION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEVER; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; LOADING DRUG DOSE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PLASMA OSMOLALITY; RECEPTOR AFFINITY; SERUM OSMOLALITY; SHORT SURVEY; SIGNAL TRANSDUCTION; SODIUM BLOOD LEVEL; VASOPRESSIN RELEASE; WATER RETENTION;

EID: 58649114510     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R17FM     Document Type: Short Survey

References (30)

1. DeVita MV, Gardenswartz MH, Konecky A, Zabetakis PM. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol. 1990;34:163-166.
2. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother. 2003;37:1694-1702.
3. Flear CT, Gill GV, Burn J. Hyponatremia: mechanisms and management. Lancet. 1981;2:26-31.
4. Miller M. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management. J Am Geriatr Soc. 2006;54:345-353.
5. Palm C, Reimann D, Gross P. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res. 2001;51:403-408.
6. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001;51:372-390.
7. Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheorghiade M, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
8. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res. 2001;51:391-402.
9. Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol. 2005;95:14B-23B.
10. Kleeman CR. The kidney in health and disease: X. CNS manifestations of disordered salt and water balance. Hosp pract, 1997;14:59-68.
11. Ayus JC, Olivero JJ, Frommer JP. Rapid correction of severe hyponatremia with intravenous hypertonic saline solution. Am J Med. 1982;72:43-48.
12. Thibonnier M. Use of vasopressin antagonists in humandiseases. Kidney Int Suppl. 1988;26:S48-S51.
13. Laszlo FA, Laszlo F Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev. 1991; 43:73-108.
14. Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252:572-574.
15. 2 receptor antagonist. Br J Pharmacol. 1992;105:787-791.
16. Nishikimi T, Kawano Y, Saito Y, Matsuoka H. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol. 1996;27:275-282.
17. 2 receptor antagonist (YM087) in the rat. Eur J Pharmacol. 1999;381:23-30.
18. 2 antagonist in men. J Pharmacol Exp Ther. 1995;272:546-551.
19. Goldsmith SR. Vasopressin antagonists in CHF: ready for clinical trials? Cardiovasc Res. 2002;54:13-15.
20. Palm C, Reimann D, Gross P. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res. 2001;51:403-408.
21. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997;282:301-308.
22. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, et al. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998;125:1463-1470.
23. Kleinfeld M, Casimir M, Borra S. Hyponatremia as observed in a chronic disease facility. J Am Geriatrics Soc. 1979;27:156-161.
24. Pham PC, Pham PM, Pham PT. Vasopressin excess and hyponatremia. Am J Kidney Dis. 2006;47:727-737.
25. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-1791.
26. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38:S69-S89.
27. 2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol Pharm Bull. 2007;30:91-95.
28. Ryan MP. Diuretics and potassium/magnesium depletion. Directions for treatment. Am J Med. 1987;82:38-47.
29. Hirota M, Ohtani H, Hanada E, Kotaki H, Sawada Y, Iga T. Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. Life Sci. 1998;62:2159-2169.
30. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N, Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447-457.